Loading the company…
Loading the company…
㈜엠큐렉스
English name as filed with DART, Korea’s corporate disclosure system · Correct the English name ›
Last updated 2026-10-09 · Korean page ›
Verification level — how far we have checked
L0 · Public records — NPS workforce · filed financials · patents — public data
A company based in Gyeonggi, founded in 2021. Industry: R&D & Professional Services. Revenue for 2025 was ₩95.0m. It has 5 employees enrolled in the National Pension Service (as of Aug 2026). It is externally audited; the latest audit opinion is “Unqualified”.
Loading…
Latest filing 2023-06-30 · latest registration 2026-01-22 · newest first
본 출원은 mRNA 백신 및 치료제의 제조를 위한 변형된 RNA에 관한 것으로서, 일 양상에 따른 변형 RNA는 특정 화학적 변형과 유전적 변형을 포함함에 따라, RNA의 투여로 인해 야기되는 선천성 면역 반응의 유도를 현격하게 낮출 수 있을 뿐만 아니라, 우수한 단백질 발현 또는 번역 효율을 나타낸 바, 치료제 및 백신 분야에서 유용하게 사용될 수 있다.
본 출원은 사스-코로나바이러스 2 감염증에 대한 RNA 백신 및 이를 위하여 제조된 폴리뉴클레오티드에 관한 것으로서, 사스-코로나바이러스-2에 대한 후천성 면역 반응을 유도하기 위한 폴리뉴클레오티드, 및 상기 폴리뉴클레오티드를 포함하는 면역원성 조성물을 제공한다.
KIPO KIPRIS · checked 2026-10-15 · newest filings first · right: registration date (filing date if not yet registered) · 2 of 2 · titles and abstracts are in Korean as filed · click a row for details ▾
For now we hold public records only (National Pension Service · DART filings · patents · registers · press). When the company files material in our IR Room, it moves to L1. We do not score or rate companies — we only state how far we have checked.
| KRW bn | 2024 | 2025 |
|---|---|---|
| Revenue | 0.0 | 0.1 |
| Cost of sales | — | 0.0 |
| Gross profit (loss) | 0.0 | 0.1 |
| Selling, general and administrative expenses | 2.2 | 1.2 |
| Operating income (loss) | (2.2) | (1.1) |
| Non-operating income | 0.8 | 0.7 |
| Other gains | 0.3 | 0.7 |
| Finance income | 0.5 | 0.0 |
| Non-operating expenses | 0.8 | 0.3 |
| Other losses | 0.0 | 0.0 |
| Finance costs | 0.8 | 0.3 |
| Profit (loss) before tax | (2.2) | (0.8) |
| Income tax expense | (0.0) | — |
| Net income (loss) | (2.2) | (0.8) |
Revenue ₩0.1bn, up 656.4% YoY.
Operating margin -1166.0% (prior -17165.4%).
Net income ₩-0.8bn.
Need more than is shown here? Ask for more information — full review report · valuation · executive teaser · IM · competitor analysis · due diligence. Tell us what you need and we will reply by email with scope, cost and timing.
Is this your company?
If anything here is wrong, tell us — we check it against the original and correct it. You do not need to join. If you would like your financials verified and this page completed, that is a separate process.